Investor action notice: moore law pllc encourages investors in altimmune inc. to contact law firm

New york , may 9, 2024 /prnewswire/ -- moore law, pllc, a securities and shareholder law firm located on wall street, is investigating potential claims against: altimmune, inc. (nasdaq: alt) *please contact fletcher@fmoorelaw.com  the investigation concerns allegations of false and/or misleading statements, as well as a failure to disclose material facts, that: (i) altimmune overstated the potential for pemvidutide to stand out from competing glp-1 agonists based on the drug's efficacy and tolerability results observed in the momentum trial; (ii) accordingly, the momentum trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than investors were led to believe; and (iii) as a result of all the foregoing, defendants had overstated altimmune's prospects for finding a strategic partner to develop pemvidutide. on february 13, 2024, kerrisdale capital published a report alleging that "a deeper examination of altimmune's data reveals a drug with little chance of competing against either the approved incumbents or the other glp-1 agonists progressing through clinical trials.
ALT Ratings Summary
ALT Quant Ranking